Evonik Industries and Eli Lilly and Co. have renewed a long-term supply agreement for active pharmaceutical ingredients (APIs) and intermediates for use in key Lilly human and veterinary drug products.

Evonik acquired Lilly’s Tippecanoe site in Lafayette, IN, in January 2010. Since then, the facility has been operating as a contract development and manufacturing organization (CDMO) for the pharma industry, serving more than 20 Evonik customers. The facility has 170 cubic meters of High Potency APIs (HPAPIs) capacity and a total of 860 cubic meters of cGMP manufacturing. The Lafayette site employs approximately 600 people.

Dr. Jean-Luc Herbeaux, head of Evonik’s Health Care Business Line, said, “The renewal of this supply agreement is clear evidence of the continued excellent collaboration between Evonik and Lilly. Evonik thanks Lilly for their great vision in transferring a well-maintained asset to Evonik in 2010 – and for their confidence in Evonik and our Tippecanoe facility as a reliable and dependable CDMO, both now, and in the future.”

Evonik’s Health Care Business offers a product and service portfolio that includes API contract manufacturing, pharmaceutical excipients, advanced food ingredients, amino acids, cell culture ingredients as well as oral and parenteral drug delivery technologies.